By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Group I antiarrhythmics > Disopyramide > Disopyramide Dosage
Group I antiarrhythmics
https://themeditary.com/dosage-information/disopyramide-dosage-10222.html

Disopyramide Dosage

Drug Detail:Disopyramide (Disopyramide [ dye-soe-pir-a-mide ])

Drug Class: Group I antiarrhythmics

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Arrhythmias

400-800 mg/day. The recommended dose for most adults is 600 mg/day. Patients < 50 kg may be given 400 mg/day.
Immediate-release form: The dose is divided and administered every 6 hours.
Extended-release form: The dose is divided and administered every 12 hours.

Renal Dose Adjustments

Immediate-release:
CrCl < 15 mL/min: Loading dose: 150 mg orally.
Maintenance dose: 100 mg orally every 24 hours.

CrCl 15-30 mL/min: Loading dose: 150 mg orally.
Maintenance dose: 100 mg orally every 12 hours.

CrCl 30-40 mL/min: Loading dose: 150 mg orally.
Maintenance dose: 100 mg orally every 8 hours.

CrCl > 40 mL/min: Loading dose: 200 mg orally.
Maintenance dose: 100 mg orally every 6 hours.

Extended-release:
CrCl <= 40 mL/min: not recommended
CrCl > 40 mL/min: Maintenance dose: 200 mg (extended-release) orally every 12 hours.

Liver Dose Adjustments

Loading dose: 200 mg orally.
Maintenance dose: 100 mg (immediate-release) orally every 6 hours or 200 mg (extended-release) orally every 12 hours.

Dose Adjustments

If rapid control of ventricular arrhythmia is necessary, an initial loading dose of 300 mg of immediate-release, or 200 mg if patient is < 50 kg is recommended.

Patients with cardiomyopathy should not be given a loading dose and should initially receive 100 mg immediate-release every 6 to 8 hours.

Precautions

US BOXED WARNING:

  • MORTALITY: In the National Heart, Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long term, multicenter, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had had a myocardial infarction more than 6 days but less than 2 years previously, an excessive mortality or non-fatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to carefully matched placebo-treated groups (3%). The average duration of treatment with encainide or flecainide in this study was 10 months. The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) is uncertain. Considering the known proarrhythmic properties of this drug and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of this drug as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.

Dialysis

Data not available

Other Comments

A limited number of patients have tolerated up to 400 mg orally every 6 hours.

Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by